Electrocardiographic Mapping and Imaging
|Study Design:||Intervention Model: Single Group Assignment
Masking: Single Blind (Participant)
Primary Purpose: Diagnostic
|Official Title:||Electrocardiographic Mapping and Imaging|
- Results of ECG Mapping [ Time Frame: 1 year ]Accuracy of the system to estimate site of arrhythmia origin, and frequency of obtaining ecg signals
|Study Start Date:||October 2013|
|Study Completion Date:||October 2013|
|Primary Completion Date:||October 2013 (Final data collection date for primary outcome measure)|
|No Intervention: ECG Mapping||
Procedure: ECG electrodes
Cardiac mapping of patients before and after ablation to develop future treatment/diagnostic options for cardiac patients.
1. Use non-invasive cardiac electric imaging to provide information as to the sites of origin of arrhythmias and sequence of cardiac activation and repolarization.
Methods and Procedures Approximately 8 patients with recorded Premature Ventricular Contractions (PVC), Wolff-Parkinson-White (WPW) or other ventricular tachycardia cases which need Ensite/Carto endocardial mapping and radiofrequency ablation treatment will be enrolled.
One day before catheterization and ablation, patients will undergo approximately 30 minutes of Body Surface Potential Mapping (BSPM) recordings with about 200 surface electrodes arranged in 20 strips, attached on his/her front and back. BSPMs will be recorded in the baseline resting rhythm.
On the day of ablation, before catheterization in the surgical room, the BSPM recording procedure will be carried out with the patient using the same technique used during the first BSPM study.
Clinical endocardial mapping data may also be obtained concurrently with BSPM recordings before the ablation procedure.
Another BSPM recording will be made 30-60 minutes after successful ablation with the patient still in normal sinus rhythm if possible. Patients will be followed up 1 month after ablation with the same method of BSPM recorded at the baseline resting rhythm.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01394965
|United States, Minnesota|
|Mayo Clinic in Rochester|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Samuel Asirvatham, MD||Mayo Clinic|